Staff

eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk...

R2 Technologies Receives Expanded FDA Clearances, Launches Backbar Treatment Kit to Broaden Patient and Provider Reach, and Announces Allies of Skin Partnership

DUBLIN, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- R2 Technologies Inc. ("R2"), the world leader in CryoAesthetics™ technology and the...

BioAdaptives, Inc. (OTC BDPT) Announces the Appointment of Flying C Bar Ranch Therapy Division as Its Exclusive Marketing Agent for Its LiveStock Impact Line of Performance Equine and Pet Supplements

Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

Highlights Include Multiple Presentations Addressing Safety and Efficacy of TrudhesaSEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL),...

Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create...

Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data

In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies...

error: Content is protected !!